Hims & Hers Health shares surged following a deal to offer Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, on its platform.

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration  AP News

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

These are the stocks posting the largest moves in early trading.

Hims & Hers Health announced its latest financial results, with GAAP EPS of $0.08, surpassing estimates by $0.03, and revenue of $617.82M, which was in-line with expectations.

This article provides a summary of significant corporate deals and transactions that occurred this week, featuring companies such as Visa, Hims & Hers Health, and Salesforce.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

These are the stocks posting the largest moves in premarket trading.

Barclays has lowered its price target on Hims & Hers Health, Inc. (HIMS) to $25 while keeping an Overweight rating.

After a 70% decline over the past year, questions arise about whether Hims & Hers Health stock can bounce back.

Hims & Hers Health, Inc. has provided a summary of its earnings call for the fourth quarter of 2025.

Hims & Hers Health, Inc. (HIMS) has announced a 2026 revenue forecast that surpasses market estimates, indicating strong projected financial performance.

Hims & Hers Health is being assessed for its potential for sustained long-term growth in the market.